NASDAQ$VIVS
Oraganovo Holdings Inc · Q1 2026 earnings
Q1 2026 earnings · · After market close · Investor relations
Briefing
VivoSim Labs reported Q1 2026, revenue of $1.2M, net loss of $3.2M, diluted EPS of $-0.12.
For Q1 2026, VivoSim Labs reported revenue of $1.2M, a net loss of $3.2M, diluted EPS was $-0.12. Management discusses operations, liquidity, and outlook in the quarterly filing.
- Revenue $1.2M.
- Net loss $3.2M.
- Diluted EPS $-0.12.
Headline financials
Revenue & EPS history
Organovo · Revenue · Quarterly
$37K
Forward guidance
The filing discusses VivoSim Labs's outlook, including capital allocation, operating priorities, and market risks relevant to the reported quarter.
Tailwinds
- VivoSim Labs cites operational priorities and demand trends supporting the outlook.
- Balance sheet and liquidity actions aim to fund growth and returns.
Headwinds
- GAAP profitability remained under pressure in Q1 2026.
- Macro, pricing, and input-cost volatility could pressure margins.
- Segment mix and one-time items may affect quarter-to-quarter comparability.
- Clinical, regulatory, or liquidity milestones dominate the near-term outlook.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2026
-0.4%
Avg return
Earnings day
+4.7%
Avg return
5 days after
+19.6%
Avg return
30 days after
46%
25 / 54 earnings
Positive
+15.3%
Q3 2013
Best reaction
-24.9%
Q4 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | +0.0% | +4.2% | -6.3% | |
| Q1 2026 | -0.5% | +3.2% | +5.9% | |
| Q4 2025 | +0.0% | +2.2% | -18.3% | |
| Q3 2025 | +0.5% | +234.2% | -31.1% | |
| Q2 2025 | -7.2% | -16.3% | +7.0% | |
| Q1 2025 | -1.3% | +0.0% | +0.0% | |
| Q4 2024 | -1.8% | +2.0% | -22.4% | |
| Q3 2024 | -7.2% | +4.1% | +5.2% | |
| Q2 2024 | -22.4% | -14.9% | -36.2% | |
| Q1 2024 | -0.6% | -4.4% | -30.2% | |
| Q4 2023 | -4.5% | -0.6% | -11.2% | |
| Q3 2023 | +6.7% | +12.4% | -5.7% | |
| Q2 2023 | +7.3% | +8.6% | +12.6% | |
| Q4 2022 | -5.3% | -3.3% | +48.3% | |
| Q3 2022 | +10.5% | +4.7% | +40.4% | |
| Q2 2022 | +1.7% | -5.8% | -18.0% | |
| Q1 2022 | -1.5% | -0.9% | -0.6% | |
| Q4 2021 | +0.7% | +0.9% | +970.6% | |
| Q3 2021 | +13.7% | +29.9% | -24.0% | |
| Q2 2021 | -0.5% | -4.1% | -15.2% | |
| Q1 2021 | +5.3% | +0.0% | -50.0% | |
| Q4 2020 | +13.2% | +15.6% | -12.5% | |
| Q3 2020 | +6.2% | -6.1% | -24.2% | |
| Q2 2020 | +3.0% | +2.6% | +28.9% | |
| Q1 2020 | -4.4% | -3.6% | -7.1% | |
| Q4 2019 | -1.5% | -16.4% | -14.5% | |
| Q3 2019 | +2.0% | +4.1% | +5.1% | |
| Q2 2019 | +0.9% | -0.9% | -8.8% | |
| Q1 2019 | -13.1% | -13.8% | -4.6% | |
| Q4 2018 | -24.9% | -26.9% | -27.5% | |
| Q3 2018 | -10.2% | -20.4% | -13.9% | |
| Q2 2018 | +4.8% | -6.8% | -5.4% | |
| Q1 2018 | -1.4% | +3.8% | +3.3% | |
| Q4 2017 | -5.2% | -6.3% | -5.2% | |
| Q3 2017 | -13.3% | -19.0% | -20.9% | |
| Q2 2017 | +8.1% | +9.7% | +14.0% | |
| Q1 2017 | +3.4% | +4.8% | -12.0% | |
| Q4 2016 | +3.3% | +1.0% | +29.3% | |
| Q3 2016 | -8.6% | — | — | |
| Q2 2016 | -3.3% | — | — | |
| Q1 2016 | -9.6% | — | — | |
| Q4 2015 | +5.8% | — | — | |
| Q3 2015 | -1.5% | — | — | |
| Q2 2015 | -1.3% | — | — | |
| Q1 2015 | +2.5% | — | — | |
| Q4 2014 | -5.6% | — | — | |
| Q3 2014 | +8.7% | — | — | |
| Q2 2014 | +13.0% | — | — | |
| Q3 2013 | +15.3% | — | — | |
| Q1 2013 | +8.0% | — | — | |
| Q4 2012 | +0.0% | — | — | |
| Q3 2012 | -13.8% | — | — | |
| Q1 2012 | +2.0% | — | — | |
| Q4 2011 | +1.0% | — | — | |
| Q3 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro